{"title":"新颖的止痒方法","authors":"Shruthi Pavana Janardhanan, Punit Saraogi","doi":"10.25259/ijsa_13_2024","DOIUrl":null,"url":null,"abstract":"About 25% of patients suffering from chronic spontaneous urticaria (CSU) are refractory to first-line therapy, making treatment challenging in these cases. There are limited options in the treatment ladder for urticaria as omalizumab is more effective in patients with raised immunoglobulin E levels; also, cost and feasibility of administration are limiting factors. Dose-related side effects often limit cyclosporine’s greater efficacy. We started tofacitinib for our 68-year-old patient who had been suffering from refractory CSU for the past 12 years and observed quick control of signs and symptoms starting within 2 weeks and good long-term control for over 9 months of which last 6 months were monotherapy.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":" 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel pitch against the itch\",\"authors\":\"Shruthi Pavana Janardhanan, Punit Saraogi\",\"doi\":\"10.25259/ijsa_13_2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"About 25% of patients suffering from chronic spontaneous urticaria (CSU) are refractory to first-line therapy, making treatment challenging in these cases. There are limited options in the treatment ladder for urticaria as omalizumab is more effective in patients with raised immunoglobulin E levels; also, cost and feasibility of administration are limiting factors. Dose-related side effects often limit cyclosporine’s greater efficacy. We started tofacitinib for our 68-year-old patient who had been suffering from refractory CSU for the past 12 years and observed quick control of signs and symptoms starting within 2 weeks and good long-term control for over 9 months of which last 6 months were monotherapy.\",\"PeriodicalId\":340475,\"journal\":{\"name\":\"Indian Journal of Skin Allergy\",\"volume\":\" 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Skin Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25259/ijsa_13_2024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Skin Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/ijsa_13_2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
约有 25% 的慢性自发性荨麻疹（CSU）患者对一线疗法难治，这使这些病例的治疗面临挑战。由于奥马珠单抗对免疫球蛋白 E 水平升高的患者更有效，因此荨麻疹治疗阶梯中的选择有限；此外，成本和用药可行性也是限制因素。与剂量相关的副作用往往限制了环孢素的疗效。68岁的患者患有难治性CSU已有12年之久，我们为他开始使用托法替尼，观察到他的症状和体征在2周内迅速得到控制，并在超过9个月的时间里得到了良好的长期控制，其中最后6个月为单药治疗。
About 25% of patients suffering from chronic spontaneous urticaria (CSU) are refractory to first-line therapy, making treatment challenging in these cases. There are limited options in the treatment ladder for urticaria as omalizumab is more effective in patients with raised immunoglobulin E levels; also, cost and feasibility of administration are limiting factors. Dose-related side effects often limit cyclosporine’s greater efficacy. We started tofacitinib for our 68-year-old patient who had been suffering from refractory CSU for the past 12 years and observed quick control of signs and symptoms starting within 2 weeks and good long-term control for over 9 months of which last 6 months were monotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
